ATE169640T1 - Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore - Google Patents

Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Info

Publication number
ATE169640T1
ATE169640T1 AT91919512T AT91919512T ATE169640T1 AT E169640 T1 ATE169640 T1 AT E169640T1 AT 91919512 T AT91919512 T AT 91919512T AT 91919512 T AT91919512 T AT 91919512T AT E169640 T1 ATE169640 T1 AT E169640T1
Authority
AT
Austria
Prior art keywords
polypeptide
prevention
treatment
antibody
malignant tumors
Prior art date
Application number
AT91919512T
Other languages
English (en)
Inventor
Pierre Chambon
Marie-Paule Kieny
Richard Lathe
Mara Hareuveni
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE169640T1 publication Critical patent/ATE169640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91919512T 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore ATE169640T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013101A FR2668064B1 (fr) 1990-10-23 1990-10-23 Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Publications (1)

Publication Number Publication Date
ATE169640T1 true ATE169640T1 (de) 1998-08-15

Family

ID=9401474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919512T ATE169640T1 (de) 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Country Status (11)

Country Link
US (3) US5861381A (de)
EP (1) EP0554344B1 (de)
JP (1) JP3195958B2 (de)
AT (1) ATE169640T1 (de)
CA (1) CA2094705C (de)
DE (1) DE69129989T2 (de)
DK (1) DK0554344T3 (de)
ES (1) ES2121791T3 (de)
FR (1) FR2668064B1 (de)
SG (1) SG96535A1 (de)
WO (1) WO1992007000A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
JPH07501942A (ja) * 1991-11-29 1995-03-02 カイロン　コーポレイション 抗ガン免疫療法用ベクター構成体
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU2021000A (en) * 1998-11-03 2000-05-22 Penn State Research Foundation, The Novel nucleic acid molecules encoding opioid growth factor receptors
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
CA2383737C (en) * 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
EP1248800A2 (de) * 1999-11-30 2002-10-16 Corixa Corporation Kompositionen und methoden zur therapie und diagnose von brustkrebs
JP5165175B2 (ja) * 2000-09-11 2013-03-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
EP2241887B1 (de) 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostika, Drogenscreening und Behandlung für Krebs
EP1531842A4 (de) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation des zellwachstums durch muc1
BR0208771A (pt) * 2001-04-02 2004-07-06 Univ Miami Office Of Technolog Peptìdeo ou poliptìdeo isolados e seus derivados, ácido nucléico codificando o mesmo, vacina copreendendo o mesmo, ácido nucléico codificando o mesmo, vetor compreendendo o referido ácido nucléico, célula hospedeira compreendendo o referido ácido nucléico, composição farmacêutica compreendendo o referido peptìdeo ou polipeptìdeo, método para tratamento ou prevençao de câncer utilizando a referida composição farmacêutica e método para induzir ou magnificar uma resposta imunológica utilizando a referida composição farmacêutica
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP3854905B2 (ja) * 2002-07-30 2006-12-06 株式会社 日立ディスプレイズ 液晶表示装置
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
EP1697399B1 (de) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1
JP2007523214A (ja) * 2004-02-23 2007-08-16 ジェンザイム コーポレイション デスレセプターリガンド誘導アポトーシスのｍｕｃ１アンタゴニスト増強方法
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP2387414A1 (de) 2009-01-13 2011-11-23 Transgene SA Verwendung einer saccharomyces cerevisiae mitochondrialen nukleinsäuren-fraktion zur immunstimulation
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
IN2012DN01577A (de) 2009-07-21 2015-06-05 Transgene Sa
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
EP4523756A3 (de) 2015-02-13 2025-05-28 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
CA1339204C (en) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
SE459115B (sv) * 1987-10-08 1989-06-05 Gas Control Equipment Ab Anordning i ventil foer gasbehaallare
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
CA2003211A1 (en) * 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
JPH06502399A (ja) 1994-03-17
CA2094705A1 (fr) 1992-04-24
JP3195958B2 (ja) 2001-08-06
SG96535A1 (en) 2003-06-16
FR2668064A1 (fr) 1992-04-24
US6203795B1 (en) 2001-03-20
DE69129989T2 (de) 1999-04-08
DK0554344T3 (da) 1999-05-17
EP0554344B1 (de) 1998-08-12
FR2668064B1 (fr) 1994-12-16
US5861381A (en) 1999-01-19
HK1012841A1 (en) 1999-08-06
CA2094705C (fr) 2007-05-15
WO1992007000A1 (fr) 1992-04-30
US6328956B1 (en) 2001-12-11
ES2121791T3 (es) 1998-12-16
EP0554344A1 (de) 1993-08-11
DE69129989D1 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
ATE169640T1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
NO913211D0 (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE132197T1 (de) Monoklonale antikörper
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
NZ527283A (en) Modified antibodies and methods of use
Hauck et al. Control of carcinoembryonic antigen gene family expression in a differentiating colon carcinoma cell line, Caco-2
NZ219338A (en) Monoclonal antibody to non-small cell lung carcinoma, its use, production and antigen
GB2278357B (en) Humanised antibodies directed against A33 antigen
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
DE69019410D1 (de) Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
AU5752490A (en) A novel tumor associated antigen
AU5790390A (en) A novel tumor associated antigen
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time